Phase 3, Randomized, Placebo-Controlled Study of Tinlarebant to Explore Safety and Efficacy in Geographic Atrophy
Status:
Recruiting
Trial end date:
2027-11-30
Target enrollment:
Participant gender:
Summary
This Phase 3, multicenter, double-masked, parallel-group, placebo-controlled, randomized,
fixed-dose clinical study is designed to evaluate the efficacy and safety of tinlarebant
(LBS-008) in subjects diagnosed with GA.